VYNE · Insider Trading
VYNE Therapeutics Inc. Common Stock
Every open-market purchase and sale reported by VYNE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-24 | Iain Stuart | CHIEF SCIENTIFIC OFFICER | F | −15,405 | −$13.83K |
| 2026-07-24 | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | F | −22,516 | −$20.21K |
| 2026-07-24 | Tyler Zeronda | CHIEF FINANCIAL OFFICER | F | −22,516 | −$20.21K |
| 2026-07-24 | David Domzalski | PRESIDENT AND CEO | F | −79,391 | −$71.26K |
| 2026-07-02 | Iain Stuart | CHIEF SCIENTIFIC OFFICER | F | −2,370 | −$1.54K |
| 2026-07-02 | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | F | −3,464 | −$2.25K |
| 2026-07-02 | David Domzalski | PRESIDENT AND CEO | F | −12,214 | −$7.95K |
| 2026-07-02 | Tyler Zeronda | CHIEF FINANCIAL OFFICER | F | −3,464 | −$2.25K |
| 2026-06-02 | David Domzalski | PRESIDENT AND CEO | A | +30,791 | +$9.55K |
| 2026-04-02 | Tyler Zeronda | CHIEF FINANCIAL OFFICER | F | −4,007 | −$2.39K |
| 2026-04-02 | David Domzalski | PRESIDENT AND CEO | F | −14,232 | −$8.50K |
| 2026-04-02 | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | F | −4,007 | −$2.39K |
| 2026-04-02 | Iain Stuart | CHIEF SCIENTIFIC OFFICER | F | −2,876 | −$1.72K |
| 2026-01-05 | Iain Stuart | CHIEF SCIENTIFIC OFFICER | F | −2,448 | −$1.42K |
| 2026-01-05 | David Domzalski | PRESIDENT AND CEO | F | −12,684 | −$7.36K |
| 2026-01-05 | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | F | −3,579 | −$2.08K |
| 2026-01-05 | Tyler Zeronda | CHIEF FINANCIAL OFFICER | F | −7,858 | −$4.56K |
| 2025-12-15 | Elisabeth Sandoval Little | Director | A | +20,000 deriv. | — |
| 2025-12-15 | Sharon Barbari | Director | A | +20,000 deriv. | — |
| 2025-12-15 | Steven L Basta | Director | A | +20,000 deriv. | — |
| 2025-12-15 | Patrick G Lepore | Director | A | +20,000 deriv. | — |
| 2025-10-02 | Iain Stuart | CHIEF SCIENTIFIC OFFICER | F | −2,453 | −$822 |
| 2025-10-02 | David Domzalski | PRESIDENT AND CEO | F | −12,676 | −$4.25K |
| 2025-10-02 | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | F | −3,581 | −$1.20K |
| 2025-10-02 | Tyler Zeronda | CHIEF FINANCIAL OFFICER | F | −3,420 | −$1.15K |
| 2025-07-02 | Iain Stuart | CHIEF SCIENTIFIC OFFICER | F | −2,453 | −$4.05K |
| 2025-07-02 | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | F | −3,581 | −$5.91K |
| 2025-07-02 | David Domzalski | PRESIDENT AND CEO | F | −12,676 | −$20.92K |
| 2025-07-02 | Tyler Zeronda | CHIEF FINANCIAL OFFICER | F | −3,420 | −$5.64K |
| 2025-06-03 | David Domzalski | PRESIDENT AND CEO | A | +8,681 | +$7.03K |
| 2025-06-03 | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | A | +1,145 | +$927 |
| 2025-04-02 | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | F | −8,828 | −$13.95K |
| 2025-04-02 | David Domzalski | PRESIDENT AND CEO | F | −30,498 | −$48.19K |
| 2025-04-02 | Iain Stuart | CHIEF SCIENTIFIC OFFICER | F | −6,044 | −$9.55K |
| 2025-04-02 | Tyler Zeronda | CHIEF FINANCIAL OFFICER | F | −8,399 | −$13.27K |
| 2025-01-23 | David Domzalski | PRESIDENT AND CEO | A | +730,000 deriv. | — |
| 2025-01-23 | Tyler Zeronda | CHIEF FINANCIAL OFFICER | A | +230,000 deriv. | — |
| 2025-01-23 | Iain Stuart | CHIEF SCIENTIFIC OFFICER | A | +230,000 deriv. | — |
| 2025-01-23 | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | A | +230,000 deriv. | — |
| 2025-01-16 | Patrick G Lepore | Director | Buy | +15,000 | +$43.80K |
| 2025-01-02 | David Domzalski | PRESIDENT AND CEO | F | −24,536 | −$82.20K |
| 2025-01-02 | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | F | −4,697 | −$15.73K |
| 2025-01-02 | Tyler Zeronda | CHIEF FINANCIAL OFFICER | F | −4,675 | −$15.66K |
| 2025-01-02 | Iain Stuart | CHIEF SCIENTIFIC OFFICER | F | −4,857 | −$16.27K |
| 2024-12-13 | Christine Borowski | Director | A | +20,000 deriv. | — |
| 2024-12-13 | Sharon Barbari | Director | A | +20,000 deriv. | — |
| 2024-12-13 | Anthony D Bruno | Director | A | +20,000 deriv. | — |
| 2024-12-13 | Elisabeth Sandoval | Director | A | +20,000 deriv. | — |
| 2024-12-13 | Patrick G Lepore | Director | A | +20,000 deriv. | — |
| 2024-12-13 | Steven L Basta | Director | A | +20,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| David Domzalski | PRESIDENT AND CEO | 6,943 | $198.29K |
| Iain Stuart | CHIEF SCIENTIFIC OFFICER | 1,919 | $54.81K |
| Mutya Harsch | CHIEF LEGAL OFFICER AND GC | 1,918 | $54.78K |
| Tyler Zeronda | CHIEF FINANCIAL OFFICER | 1,498 | $42.78K |
| Patrick G Lepore | Director | 1,029 | $29.39K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VYNE quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.